Evidence map›Paper›PMID 39767909›Full record

ArticleChildren (Basel, Switzerland)2024

Making a Difference from Day One: The Urgent Need for Universal Neonatal Hearing Screening.

Michail Athanasopoulos, Pinelopi Samara, Georgios Batsaouras, Ioannis Athanasopoulos

Abstract read
In one paragraph

Article in Children (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michail AthanasopoulosDepartment of Audiology, Otology, Neurotology & Cochlear Implant Unit, Athens Pediatric Center, 15125 Athens, Greece.ORCID 0000-0003-0592-6921
Pinelopi SamaraChildren's Oncology Unit "Marianna V. Vardinoyannis-ELPIDA", Aghia Sophia Children's Hospital, 11527 Athens, Greece.ORCID 0009-0001-2249-7068
Georgios BatsaourasDepartment of Otolaryngology, University Hospital of Patras, 26504 Patras, Greece.ORCID 0009-0002-5685-4999
Ioannis AthanasopoulosDepartment of Audiology, Otology, Neurotology & Cochlear Implant Unit, Athens Pediatric Center, 15125 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neonatal hearing screening (NHS) is a critical public health measure for early identification of hearing loss, ensuring timely access to interventions that can dramatically improve a child's language development, cognitive abilities, and social inclusion. Beyond clinical benefits, NHS provides long-term advantages in education and quality of life. Given that congenital hearing loss affects approximately 1-2 in every 1000 newborns worldwide, the case for universal screening is clear. Countries like the United States and Australia have successfully implemented NHS, leading to earlier diagnoses, improved language development, and better educational outcomes. In Europe, while many nations have adopted NHS, consistency remains a challenge. Countries such as Norway and the United Kingdom stand out for their well-established systems, whereas others, like Greece, have made notable progress but have yet to mandate NHS nationwide. This highlights the need for cohesive national policies across Europe to ensure universal coverage. Screening methods such as Transient Evoked Otoacoustic Emissions (TEOAE) and Automated Auditory Brainstem Response (AABR) are established tools for detecting hearing impairments in neonates. Despite their demonstrated efficacy, NHS remains inconsistent globally, particularly in low- and middle-income regions that lack mandatory policies or access to reliable screening technologies. This perspective advocates for the urgent need to make NHS mandatory in all countries, emphasizing its societal benefits and cost-effectiveness. Early diagnosis supports prompt intervention, like hearing aids or cochlear implants, which are most effective when implemented before six months. It also empowers families to make informed decisions, fosters educational inclusion, and mitigates the social and emotional challenges of undiagnosed hearing loss. Policymakers, healthcare providers, and international organizations must prioritize universal NHS to ensure no child is left behind due to unaddressed hearing loss.

Indexed as

automated auditory brainstem responsecochlear implantscongenital hearing lossearly detectionearly interventionhearing aidsneonatal hearing screeningtransient evoked otoacoustic emissions

Identifiers

PMID39767909
PMCPMC11674813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.